真实世界中免疫检查点抑制剂相关不良反应的发生率和管理：基于回顾性理赔数据分析。
Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis.
机构信息
Humana Inc., Louisville, KY, USA.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
出版信息
Cancer Invest. 2021 Nov;39(10):789-796. doi: 10.1080/07357907.2021.1913502. Epub 2021 Sep 27.
PURPOSE
We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs.
METHODS
irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018.
RESULTS
Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs.
CONCLUSION
These data underscore the needs for tailored irAE diagnostic and management pathways.
目的
我们评估了接受抗 PD(L)1 ICIs 治疗的患者的真实世界免疫相关不良事件（irAEs）谱和模式。
方法
我们使用医疗保险优势处方药计划中接受抗 PD(L)-1 治疗且在 2014 年 9 月 1 日至 2018 年 2 月 28 日之间接受至少 1 剂治疗的患者的医疗和药物索赔来定义 irAEs。
结果
46.6%的患者停止治疗，10.3%的患者暂停治疗并随后重新开始。虽然毒性谱与年龄无关，但患有 irAEs 的患者的 RiskRx-V 合并症指数更高。
结论
这些数据强调了需要制定针对 irAE 的诊断和管理途径。
Zotero 插件